Gemcitabine Plus<i>nab</i>-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

20111,043 citationsJournal Articlebronze Open Access

Authors

The regimen of nab-paclitaxel plus gemcitabine has tolerable adverse effects with substantial antitumor activity, warranting phase III evaluation.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 29, Issue 34, pp. 4548-4554

Field-Weighted Citation Impact: 36.95